{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281672","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.226880+00:00","generated_at":"2026-05-16T19:57:09.331636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene","bullets":["Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.","Cash, cash equivalents and marketable securities $680.3M, sufficient to fund operations into H1 2028.","Initiated rolling BLA submission to FDA for cretostimogene monotherapy in HR BCG-unresponsive NMIBC.","R&D expenses $27.9M (up 42% YoY), G&A $23.3M (up 168% YoY) driven by clinical trials and headcount.","Completed enrollment of Phase 3 PIVOT-006 trial in IR NMIBC 10 months ahead of schedule."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281672","json":"https://secwatch.observer/filing/0001193125-25-281672.json","markdown":"https://secwatch.observer/filing/0001193125-25-281672.md","text":"https://secwatch.observer/filing/0001193125-25-281672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/0001193125-25-281672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:57:09.331636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}